Skip to content
Oncology Research Hub

Bethesda, Maryland

Cancer clinical trials in Bethesda, MD

142 cancer studies are recruiting participants at sites in Bethesda as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.

Call (888) 343-1186
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Bethesda at a glance

  • 142 studies are recruiting at a site in Bethesda.
  • By phase: Early Phase 1 (1), Phase 1 (17), Phase 1/2 (12), Phase 2 (30), Phase 2/3 (2), Phase 3 (30), Phase 4 (1), No phase (4), Observational (45). Studies of devices and behavioral approaches have no phase.
  • By sponsor: government (92), industry (38), university, hospital or other (12).
  • By research area: Lymphoma (51), Lung Cancer (32), Breast Cancer (23), Prostate Cancer (22), Pancreatic Cancer (8), Melanoma (6).
  • Most recent update to one of these records: November 16, 2026.

Breast cancer studies recruiting in Bethesda

Basic details from each study's public record (the 30 most recently updated of 142). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases

    • Observational
    • Ages 18 to 120
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT07619534 · updated
  2. Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

    • Phase 2
    • Ages 18 to 72
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT01174121 · updated
  3. Genomic Services Research Program

    • Observational
    • From 1 month, up to 105 years
    • All sexes
    Sponsor
    National Human Genome Research Institute (NHGRI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT02595957 · updated
  4. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    National Institutes of Health Clinical Center · Walter Reed National Military Medical Center
    Registry record
    NCT05564377 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Bethesda, MD on ClinicalTrials.gov.

Lung cancer studies recruiting in Bethesda

  1. Evaluation for NCI Surgery Branch Clinical Research Protocols

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT00001823 · updated
  2. Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer

    • Observational
    • Ages 2 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT00033137 · updated
  3. Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

    • Observational
    • Ages 2 to 100
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT01950572 · updated
  4. Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

    • Observational
    • Ages 18 to 120
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT02682667 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Bethesda, MD on ClinicalTrials.gov.

Prostate cancer studies recruiting in Bethesda

  1. Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

    • Phase 2
    • Ages 18 to 120
    • Male participants
    Sponsor
    National Cancer Institute (NCI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT07574541 · updated
  2. Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

    • Phase 1/2
    • Ages 18 to 120
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT07667400 · updated
  3. Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study site
    Suburban Hospital
    Registry record
    NCT04423211 · updated
  4. Collection of Blood From Patients With Prostate Cancer

    • Observational
    • Ages 18 and older
    • Male participants
    Sponsor
    National Cancer Institute (NCI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT00923221 · updated
  5. Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy

    • Observational
    • Ages 18 to 120
    • Male participants
    Sponsor
    National Cancer Institute (NCI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT01834001 · updated
  6. Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue

    • Observational
    • Ages 18 and older
    • Male participants
    Sponsor
    National Cancer Institute (NCI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT02594202 · updated
  7. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT03866382 · updated
  8. Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL

    • Observational
    • Ages 18 and older
    • Male participants
    Sponsor
    National Cancer Institute (NCI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT05588128 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Bethesda, MD on ClinicalTrials.gov.

Melanoma studies recruiting in Bethesda

  1. Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

    • Phase 2
    • Ages 18 to 120
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT05155033 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Bethesda, MD on ClinicalTrials.gov.

Lymphoma studies recruiting in Bethesda

  1. Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

    • Phase 2
    • Ages 12 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT03258567 · updated
  2. A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...

    • No phase
    • Ages 1 to 25
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT05621291 · updated
  3. ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Newave Pharmaceutical Inc
    Study site
    The Center for Cancer and Blood Disorders-Bethesda
    Registry record
    NCT07342478 · updated
  4. Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 1
    • Ages 18 to 120
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT07572136 · updated
  5. A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    American Oncology Partners, P.A. ( Site 0185)
    Registry record
    NCT06717347 · updated
  6. Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

    • Observational
    • Ages 18 to 110
    • All sexes
    Sponsor
    National Heart, Lung, and Blood Institute (NHLBI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT00923507 · updated
  7. Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT01087333 · updated
  8. Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

    • Phase 1/2
    • Ages 18 to 120
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT03223610 · updated
  9. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Walter Reed National Military Medical Center
    Registry record
    NCT04269902 · updated
  10. A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Grifols Therapeutics LLC
    Study site
    GC2202 Study Site 111
    Registry record
    NCT05645107 · updated
  11. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Walter Reed National Military Medical Center
    Registry record
    NCT05675410 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Bethesda, MD on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Bethesda

  1. Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

    • Phase 2
    • Ages 12 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    National Institutes of Health ( Site 0125)
    Registry record
    NCT04924075 · updated
  2. Cancer in Inherited Bone Marrow Failure Syndromes

    • Observational
    • From 1 day, up to 100 years
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    National Institutes of Health Clinical Center
    Registry record
    NCT00027274 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Bethesda, MD on ClinicalTrials.gov.

Ask about studies near Bethesda

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Maryland

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-1186

or send a short form

How should we reach you?

Call